Safety and Efficacy of Pharmacologic Weight Loss in Patients with Cirrhosis

Overview

Journal Obes Sci Pract

Date 2021 Apr 12

PMID 33841885

Citations 1

Authors

Ali Y Fakhreddine

Samantha Bagsic

Ken Fujioka

Catherine T Frenette

Affiliations

Soon will be listed here.

Abstract

Background: Obesity poses unique risks in patients with advanced liver fibrosis; however, given surgical risks of bariatric surgery in cirrhosis treatment recommendations are currently limited to lifestyle interventions. This study seeks to inform a potential treatment gap by describing the safety and efficacy of pharmacologic weight loss in patients with advanced liver disease.

Methods: A retrospective chart review of the electronic medical record was conducted for all patients in the Scripps Health system from 2005 to 2017 with established advanced liver fibrosis that were prescribed medications associated with weight loss. The primary outcome was safety as defined by the model for end-stage liver disease (MELD) score. Secondary outcomes included total body weight loss, reasons for medication discontinuation, medication adverse events, and hospitalization before and after medication initiation.

Results: Thirty-eight patients and 63 prescriptions were included in the final analysis. The most frequently prescribed medication associated with weight loss was metformin (63%, = 24) followed by a GLP-1 agonist (39%, = 15). There was no significant effect of weight-loss medication on MELD score ( > 0.18) or number of hospitalizations when adjusting for subject ( > 0.26). There was a significant adjusted mean weight loss of 2.2 kg ( < 0.02) following prescription of a medication associated with weight loss. The Federal Drug Administration-approved anti-obesity medications as a group resulted in a significant adjusted weight loss of 7.22 kg ( < 0.013). In a linear mixed-effects model accounting for subjects, weight loss was not independently associated with a change in MELD ([51] = -1.972, > 0.05).

Conclusion: Pharmacologic weight loss in patients with advanced liver fibrosis appears feasible based on preliminary safety and efficacy outcomes in this study. Future prospective studies are warranted to evaluate a potential significant treatment gap in the management of obesity in this vulnerable population.

Citing Articles

Five-year Weight Loss Maintenance With Obesity Pharmacotherapy.

Weintraub M, DAngelo D, Tchang B, Sahagun A, Andre C, Aronne L J Clin Endocrinol Metab. 2023; 108(9):e832-e841.

PMID: 36810608 PMC: 10438886. DOI: 10.1210/clinem/dgad100.

References

Salman M, Mikhail H, Nafea M, Sultan A, Elshafey H, Tourky M . Impact of laparoscopic sleeve gastrectomy on fibrosis stage in patients with child-A NASH-related cirrhosis. Surg Endosc. 2020; 35(3):1269-1277. DOI: 10.1007/s00464-020-07498-4. View

Sujanani S, Elfishawi M, Zarghamravanbaksh P, Cuevas Castillo F, Reich D . Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature. Case Rep Endocrinol. 2020; 2020:6724504. PMC: 7044483. DOI: 10.1155/2020/6724504. View

Armstrong M, Gaunt P, Aithal G, Barton D, Hull D, Parker R . Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2015; 387(10019):679-690. DOI: 10.1016/S0140-6736(15)00803-X. View

Bohula E, Wiviott S, McGuire D, Inzucchi S, Kuder J, Im K . Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018; 379(12):1107-1117. DOI: 10.1056/NEJMoa1808721. View

Wing R, Bolin P, Brancati F, Bray G, Clark J, Coday M . Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369(2):145-54. PMC: 3791615. DOI: 10.1056/NEJMoa1212914. View

Mosko J, Nguyen G . Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol. 2011; 9(10):897-901. DOI: 10.1016/j.cgh.2011.07.007. View

Ortiz V, Berenguer M, Rayon J, Carrasco D, Berenguer J . Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 2002; 97(9):2408-14. DOI: 10.1111/j.1572-0241.2002.05995.x. View

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L . Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149(2):367-78.e5. DOI: 10.1053/j.gastro.2015.04.005. View

Larsson S, Wolk A . Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007; 97(7):1005-8. PMC: 2360408. DOI: 10.1038/sj.bjc.6603932. View

10.

Sinclair M, Gow P, Grossmann M, Angus P . Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther. 2016; 43(7):765-77. DOI: 10.1111/apt.13549. View

11.

Garvey W, Mechanick J, Brett E, Garber A, Hurley D, Jastreboff A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. Endocr Pract. 2016; 22 Suppl 3:1-203. DOI: 10.4158/EP161365.GL. View

12.

Welzel T, Graubard B, Zeuzem S, El-Serag H, Davila J, McGlynn K . Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011; 54(2):463-71. PMC: 4141525. DOI: 10.1002/hep.24397. View

13.

Tang H, Yang K, Li X, Song Y, Han J . Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2020; 29(2):161-172. DOI: 10.1002/pds.4943. View

14.

Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta F, Boulton D . Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011; 33(11):1798-808. DOI: 10.1016/j.clinthera.2011.09.011. View

15.

Watt K . Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation. Liver Transpl. 2012; 18 Suppl 2:S52-8. DOI: 10.1002/lt.23515. View

16.

Montano-Loza A, Angulo P, Meza-Junco J, Prado C, Sawyer M, Beaumont C . Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016; 7(2):126-35. PMC: 4864157. DOI: 10.1002/jcsm.12039. View

17.

Yanovski S, Yanovski J . Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2013; 311(1):74-86. PMC: 3928674. DOI: 10.1001/jama.2013.281361. View

18.

Ueda P, Svanstrom H, Melbye M, Eliasson B, Svensson A, Franzen S . Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018; 363:k4365. PMC: 6233755. DOI: 10.1136/bmj.k4365. View

19.

Martin P, DiMartini A, Feng S, Brown Jr R, Fallon M . Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014; 59(3):1144-65. DOI: 10.1002/hep.26972. View

20.

Minambres I, Rubio M, de Hollanda A, Breton I, Vilarrasa N, Pellitero S . Outcomes of Bariatric Surgery in Patients with Cirrhosis. Obes Surg. 2018; 29(2):585-592. DOI: 10.1007/s11695-018-3562-8. View